Member Info for BuenaVista

Not such a 'coincidence' that Avacta is using MSK, where Bachovchin's son Daniel has a lab. But noteworthy that little Avacta has not just enrolled top US oncologists for the SAB but that the trial is being carried out at the two premier US cancer research sites (and the Fred Hutchinson Cancer Center ain't bad either).

That was the hard part - composing a post in LSE's ½" high frame. This is the easy part - straight from Google:

The top US cancer research centers consistently cited in rankings include The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. The Mayo Clinic and The Johns Hopkins Hospital also frequently appear on top lists.

Here's a more detailed look at these and other top centers:

Consistently Ranked Top:

The University of Texas MD Anderson Cancer Center:

Often ranked as the #1 cancer center in the US and internationally, known for its extensive research and specialized treatments.

Memorial Sloan Kettering Cancer Center:

A leading center with a strong focus on both research and clinical care, consistently ranked in the top 3.

Mayo Clinic:

Recognized for its comprehensive approach to cancer care, including research, treatment, and patient support.

The Johns Hopkins Hospital:

A leading institution with a strong history of cancer research and innovative treatments.

Other Highly Ranked Centers:

Dana-Farber Cancer Institute: Known for its specialized research in various cancer types, including pediatric cancer.

City of Hope Comprehensive Cancer Center: A growing center with a focus on innovative treatments and cutting-edge research.

Moffitt Cancer Center: Recognized for its commitment to clinical trials and developing new therapies.

Cleveland Clinic Taussig Cancer Institute: A comprehensive cancer center with expertise in various types of cancer.

Roswell Park Cancer Institute and UCSF Medical Center: Also consistently ranked among the top cancer centers in the US.

These rankings are based on various factors, including research output, clinical expertise, and patient outcomes. The specific ranking of centers may vary slightly depending on the source.

It also worked with AVA3996 in preclinical as well so it's not as if AVA6000 and AVA6103 are the only proofs of concept in preclinical.

Just bin the trader. It adds nothing.

Interesting Spotlighht video. And some interesting body language.

As a chemist by training who has worked with a group of brilliant scientists - folk who went on to head UK and global R&D in top pharma companies; head the Covid vaccine taskforce; and start and head numerous small biotech companies - on site-specific drug delivery, aka targetted drug delivery, I can tell you that these British guys at Avacta have found the Holy Grail of drug discovery - targetted sustained delivery.

We didn't succeed with our projects at the time because we didn't have the tech tools, especially computational chemistry, or the detailed biological knowledge 30-35 years ago that is available now, but it was a very forward-thinking initiative to tackle such a complex problem, so well done to the Avacta guys who have succeeded nbow! I look forward to seeing the patent(s) when published.

Charwoman in CC's kitchen area

When AI got it's knickers twisted.

Thanks o_m

📰

Additionally, the new CEO of Avacta, Martin Branch, previously held a partnership at L.E.K. Consulting.

Why did no one tells us????

Read all about here: https://tinyurl.com/ycy5pp7p

So has anyone ever seen anything on the internet that directly links L E K Consulting with Avacta?

Avacta homepage shouts:

"Expanding the reach of highly potent cancer therapies with pre|CISION®"

"We believe in hope without compromise"

How do they grab you as straplines? For me, it all reads like it was designed inhouse ...and they couldn't decide which one was best, so used both. And I think you all know who I mean by 'inhouse'.

Speak you Engerlish?

I've just had a look at Sam's Chat Post Distribution. Very instructive. Rainbow chaser.

The time to buy is when the bashers stop bashing.

I've just come back from the moon and have the staircase to sell you.

McMuff has become very loud with all this bashing. He's not exactly a subtle trader is he.

@AlbertoFrog, keep trying to knock the SP down to your reentry point.😂😂😂

@Sagetrade, Well, it's a fact that several eminent physicians DO think we have the holy grail here. And it's also a fact that pharmaceutical clinical developmeny takes a long time and there are several hoops to be jumped through until, for a startup business, BOOM, the long-sought deal comes through.

As to the management's competence, I'm not convinced they understand AIM or their investors.

The cash one was a few days early, the 18th. Considering the Easter weekend, I guess they needed today, when the workday processes started again, to get whatever they're going to do organised and signed off.

Same story here: https://www.reuters.com/business/healthcare-pharmaceuticals/trump-health-policy-uncertainty-sends-biotech-sector-into-deeper-slump-2025-04-14/

And this is how it starts (sound familiar?): "Sector had suffered post-pandemic slump before Trump took office"